InvestorsHub Logo
Followers 11
Posts 1565
Boards Moderated 0
Alias Born 09/19/2006

Re: None

Monday, 06/18/2018 11:28:51 AM

Monday, June 18, 2018 11:28:51 AM

Post# of 6378
What is going on with this company?

No news. No indication that funds are being raised. No partnerships. No info on the trials. I sure hope we are in a "quiet period" as the other options for the lack of company communication are not good.

ARWR completes enrollment in phase I and reaches 1.2 billion in market cap.

07:48 AM EDT, 06/18/2018

(MT Newswires) -- Arrowhead Research (ARWR) said pre-market Monday that it completed enrollment of a phase 1 clinical study of ARO-AAT, a second generation subcutaneously administered RNA interference therapeutic for a rare genetic liver disease linked to alpha-1 antitrypsin deficiency.

BPTH is in Phase II and unable crack 20 million in market cap.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News